| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43596 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
May, 2017
(6 years ago) | |
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5843946 | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Dec, 2015
(8 years ago) | |
|
US5843946 (Pediatric) | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Jun, 2016
(7 years ago) | |
| USRE42889 | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
| USRE43802 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
|
USRE42889 (Pediatric) | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43802 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43596 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Nov, 2017
(6 years ago) | |
| US9889115 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US8597876 | JANSSEN PRODS | Method of treating HIV infection |
Jun, 2019
(4 years ago) | |
| US7470506 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
|
US7470506 (Pediatric) | JANSSEN PRODS | Fitness assay and associated methods |
Dec, 2019
(4 years ago) | |
|
US8597876 (Pediatric) | JANSSEN PRODS | Method of treating HIV infection |
Dec, 2019
(4 years ago) | |
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(3 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
Prezcobix is owned by Janssen Prods.
Prezcobix contains Cobicistat; Darunavir.
Prezcobix has a total of 19 drug patents out of which 14 drug patents have expired.
Expired drug patents of Prezcobix are:
- US5843946
- US5843946*PED
- USRE42889
- USRE43802
- USRE42889*PED
- USRE43802*PED
- USRE43596*PED
- US9889115
- US8597876
- US7470506
- US7470506*PED
- US8597876*PED
- USRE43596
- US8518987
Prezcobix was authorised for market use on 29 January, 2015.
Prezcobix is available in tablet;oral dosage forms.
Prezcobix can be used as treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase, treatment of hiv-1 infection in adults with no darunavir resistance-associated substitutions.
Drug patent challenges can be filed against Prezcobix from 27 August, 2016.
The generics of Prezcobix are possible to be released after 06 October, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv-1 infection in adults with no darunavir resistance-associated substitutions; Treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition con...
Dosage: TABLET;ORAL
PREZCOBIX family patents
